Nang Kuang Pharmaceutical Co Ltd
Nang Kuang Pharmaceutical Co., Ltd. manufactures, processes, trades in, imports, and exports pharmaceuticals and medical devices in Taiwan, China, Japan, the United States, and internationally. The company offers ready to use injections, such as prefilled syringe injections and premixed IV infusions; anti-aging and preventive medicines; chemotherapy and oncology products; and non-PVC IV infusion.… Read more
Nang Kuang Pharmaceutical Co Ltd (1752) - Total Assets
Latest total assets as of December 2025: NT$3.82 Billion TWD
Based on the latest financial reports, Nang Kuang Pharmaceutical Co Ltd (1752) holds total assets worth NT$3.82 Billion TWD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nang Kuang Pharmaceutical Co Ltd - Total Assets Trend (2009–2025)
This chart illustrates how Nang Kuang Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Nang Kuang Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Nang Kuang Pharmaceutical Co Ltd's total assets of NT$3.82 Billion consist of 39.0% current assets and 61.0% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 9.0% |
| Accounts Receivable | NT$253.40 Million | 6.6% |
| Inventory | NT$663.38 Million | 17.4% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how Nang Kuang Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nang Kuang Pharmaceutical Co Ltd's current assets represent 39.0% of total assets in 2025, an increase from 27.2% in 2009.
- Cash Position: Cash and equivalents constituted 9.0% of total assets in 2025, up from 2.3% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 17.4% of total assets.
Nang Kuang Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Nang Kuang Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931
|
China | CN¥3.82 Billion |
|
Blue Sail Medical Co Ltd
SHE:002382
|
China | CN¥16.46 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥28.98 Billion |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
China | CN¥5.35 Billion |
|
Inix Technologies Holdings Bhd
KLSE:0094
|
Malaysia | RM72.53 Million |
|
Focus Point Holdings Bhd
KLSE:0157
|
Malaysia | RM328.19 Million |
|
Careplus Group Bhd
KLSE:0163
|
Malaysia | RM286.61 Million |
|
LKL International Bhd
KLSE:0182
|
Malaysia | RM173.46 Million |
Nang Kuang Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Nang Kuang Pharmaceutical Co Ltd generates 0.57x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Nang Kuang Pharmaceutical Co Ltd generates $6.38 in net profit.
Nang Kuang Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.40 | 1.27 | 1.58 |
| Quick Ratio | 0.78 | 0.72 | 0.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$427.81 Million | NT$ 313.17 Million | NT$ 514.18 Million |
Nang Kuang Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Nang Kuang Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.50 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 0.3% |
| Total Assets | NT$3.82 Billion |
| Market Capitalization | $46.91 Million USD |
Valuation Analysis
Below Book Valuation: The market values Nang Kuang Pharmaceutical Co Ltd's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Nang Kuang Pharmaceutical Co Ltd's assets grew by 0.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Nang Kuang Pharmaceutical Co Ltd (2009–2025)
The table below shows the annual total assets of Nang Kuang Pharmaceutical Co Ltd from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$3.82 Billion | +0.28% |
| 2024-12-31 | NT$3.81 Billion | -1.12% |
| 2023-12-31 | NT$3.86 Billion | +7.58% |
| 2022-12-31 | NT$3.58 Billion | +4.54% |
| 2021-12-31 | NT$3.43 Billion | +5.18% |
| 2020-12-31 | NT$3.26 Billion | -0.83% |
| 2019-12-31 | NT$3.29 Billion | +8.58% |
| 2018-12-31 | NT$3.03 Billion | -9.19% |
| 2017-12-31 | NT$3.33 Billion | +5.11% |
| 2016-12-31 | NT$3.17 Billion | +4.16% |
| 2015-12-31 | NT$3.05 Billion | +10.52% |
| 2014-12-31 | NT$2.76 Billion | +5.71% |
| 2013-12-31 | NT$2.61 Billion | +7.90% |
| 2012-12-31 | NT$2.42 Billion | +15.42% |
| 2011-12-31 | NT$2.09 Billion | +13.04% |
| 2010-12-31 | NT$1.85 Billion | +8.46% |
| 2009-12-31 | NT$1.71 Billion | -- |